Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus

World Journal of Gastroenterology

Volumn 11, Issue 16, 2005, Pages 2518-2521

  Pan, Lei ^a   Jia, Zhan Sheng ^a   Chen, Lin ^a   Fu, En Qing ^a   Li, Guang Yu ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti tuberculosis; HBV

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; AMIKACIN; ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; GLOBULIN; ISONIAZID; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; APPETITE DISORDER; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; FATIGUE; FEMALE; HEPATITIS B; HUMAN; INCIDENCE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA;

EID: 18744408485     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i16.2518     Document Type: Article

References (18)

1. Zhu LZ. The treatment of MDR-TB. Zhonghua Jiehe He Huxi Zazhi 2000; 23: 77-78
2. Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 2002; 359: 775-780
3. Chen L, Jia ZS, Yao QM. Analysis of clinical characteristics of 59 old pulmonary tuberculosis patients. Disi Junyi Daxue Xuebao 2000; 21: 872-874
4. Wong WM, Wu PC, Yuen MF, Cheng CC, Yew WW, Wong PC, Tam CM, Leung CC, Lai CL. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206
5. Sadaphal P, Astemborski J, Graham NM, Sheely L, Bonds M, Madison A, Vlahov D, Thomas DL, Sterling TR. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001; 33: 1687-1691
6. Pozniak A. Mycobacterial diseases and HIV. J HIV Ther 2002; 7: 13-16
7. Colebunders R, Lambert ML. Management of co-infection with HIV and TB. BMJ 2002; 324: 802-803
8. Tahaoglu K, Atac G, Sevim T, Tarun T, Yazicioglu O, Horzum G, Gemci I, Ongel A, Kapakli N, Aksoy E. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001; 5: 65-69
9. Saigal S, Agarwal SR, Nandeesh HP, Sarin SK. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol 2001; 16: 1028-1032
10. Zou JX, Liou MX, Qi WM, Guo TC, Jin FG. Polymerase chain reaction and intensified kinyoun in diagnosis of L-form tubercle bacillus infection. Disi Junyi Daxue Xuebao 2000; 21: 198-199
11. Zhang PY. Diagnosis and treatment of tuberculosis. Zhonghua Jiehe He Huxi Zazhi 2001; 24: 70-74
12. Yew WW, Chau CH, Wong PC, Lee J, Wong CF, Cheung SW, Chan CY, Cheng AF. Ciprofloxacin in the management of pulmonary tuberculosis in the face of hepatic dysfunction. Drugs Exp Clin Res 1995; 21: 79-83
13. Yew WW, Lee J, Wong PC, Kwan SY. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res 1992; 12: 173-178
14. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9: 2026-2030
15. Qu YW, Guo Y, Zhao GD, He HZ, Liu Y. The mechanism and prevention of hepatic damage caused by anti-TB drug. Zhongguo Fanglao Zazhi 2001; 23: 56-57
16. van den Brande P, van Steenbergen W, Vervoort G, Demedts M. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995; 152 (5Pt 1): 1705-1708
17. Lu Y, Zhu LZ, Duan LS. The anti-TB effects of fluoroquinolone. Zhonghua Jiehe He Huxi Zazhi 1999; 22: 693-695
18. Mitchell I, Wendon J, Fitt S, Williams R. Anti-tuberculous therapy and acute liver failure. Lancet 1995; 345: 555-556